萬春醫藥 BYSI 深 滬
已收盤 08-01 16:00:00 美东时间
2.07
+0.020
+0.98%
華盛通- 最 高2.10
- 今 開1.99
- 成交量 3.89万股
- 最 低 1.99
- 昨 收 2.05
- 總市值 8345.47万
- 52周最高 3.44
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 0.98
- 委 比 -96.20%
- 總股本 4031.63万
- 歷史最高 48.49
- 量 比 3.06
- 振 幅 5.37%
- 歷史最低 0.542
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BeyondSpring Drug Triggers Immune Response in Patients Who Failed Prior Cancer Immunotherapy
BeyondSpring Inc. (NASDAQ:BYSI) today announced publication of a human clinical study in Med (Cell Press) demonstrating that Plinabulin, when combined with radiation and a checkpoint inhibitor, induces
07-07 19:04
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
BeyondSpring Inc.的Plinabulin在与放疗和PD-1抑制剂联合治疗中，在8种肿瘤类型中取得23%客观缓解率和54%疾病控制率。研究揭示GEF-H1免疫基因表达可能是预测性生物标志物，并证实Plinabulin通过GEF-H1信号促进树突状细胞成熟，增强抗肿瘤免疫反应。该研究发表在《Med》杂志上。
07-07 11:00
小坑，2只打新！
关键指标【仅供参考】 1、沪深300股债利差择时模型：6.17%，维持100%偏股基金。（持有资金或新增资金均配置节节高混合/雄霸赛道偏股等组合）。 2、万得全...
06-11 08:15
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
BeyondSpring Inc. announced interim phase 2 data from the 303 Study at the 2025 ASCO Annual Meeting. The study evaluated Plinabulin, pembrolizumab, and docetaxel in 47 metastatic NSCLC patients who progressed on PD-1/L1 inhibitors. Key results include a median PFS of 6.8 months, a Disease Control Rate of 77.3%, and a 15-month OS rate of 78%, with the combination well-tolerated. The data suggest Plinabulin's potential to reverse resistance to chec...
06-03 11:00
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
BeyondSpring Inc. will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, highlighting the 303 Study on the combination of pembrolizumab, plinabulin, and docetaxel for patients with metastatic NSCLC who progressed on first-line immune checkpoint inhibitors. The presentation, titled "Phase 2 Study of Pembrolizumab (Pembro) plus Plinabulin (Plin) and Docetaxel (Doc)...", will discuss initial efficac...
05-28 11:00
BeyondSpring GAAP EPS of -$0.08
BeyondSpring press release (NASDAQ:BYSI): Q1 GAAP EPS of -$0.08. Cash and cash equivalents of $2.92 million. More on BeyondSpring Financial information for BeyondSpring
05-13 05:25
BeyondSpring Q1 EPS $(0.08) Down From $0.11 YoY
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.08) per share. This is a 172.73 percent decrease over earnings of $0.11 per share from the same period last year.
05-13 05:05
美股异动丨昶洧汽车跌28.47%，为跌幅最大的中概股
格隆汇5月8日｜中概股收盘跌幅前五的个股为：昶洧汽车跌28.47%，新世纪储运跌26.04%，见知教育跌22.54%，万春医药跌20.19%，有信科技跌19%...
05-08 08:35
BeyondSpring’s 2024 Progress and Strategic Milestones
Beyondspring ( ($BYSI) ) has released its Q4 earnings. Here is a breakdown of t...
03-29 12:00
